United States Assisted Reproductive Technology Market Size, Growth & Forecast 2025–2033

United States Assisted Reproductive Technology Market Overview

The United States Assisted Reproductive Technology (ART) Market is projected to reach US$ 9.31 billion by 2033, rising from US$ 6.01 billion in 2024, with a CAGR of 4.98% during 2025–2033, according to Renub Research.

This remarkable growth is being fueled by rising infertility rates, advancements in ART procedures, wider insurance coverage, increasing societal acceptance of fertility treatments, and the growing use of genetic testing and embryo freezing.

As modern lifestyles, delayed marriages, and career priorities affect reproductive timelines, the U.S. is witnessing a surge in demand for fertility solutions that are technologically advanced, reliable, and ethically managed. Assisted reproductive technology has emerged as a lifeline for millions of couples and individuals striving to conceive — offering a combination of medical innovation, personal empowerment, and social transformation.

Understanding Assisted Reproductive Technology (ART)

Assisted Reproductive Technology (ART) encompasses medical techniques designed to address infertility and improve the chances of conception. Procedures like In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Embryo Cryopreservation, and Artificial Insemination (AI-IUI) form the cornerstone of this market.

These technologies manipulate eggs and sperm outside the human body and are often utilized when traditional fertility treatments fail or when patients face genetic issues, advanced maternal age, or unexplained infertility. ART not only fulfills the biological dream of parenthood but also supports genetic screening, fertility preservation, and reproductive planning for diverse family structures, including single parents and LGBTQ+ individuals.

Market Drivers Fueling Growth

1. Rising Infertility Rates and Growing Awareness

Infertility affects an estimated 1 in 8 couples in the U.S., according to the CDC. This growing prevalence has led to a surge in fertility consultations and demand for advanced ART services. Moreover, public awareness campaigns and celebrity openness about fertility struggles have helped reduce stigma and promote treatment acceptance.

Government and non-government organizations are actively raising awareness about the importance of early fertility assessment and treatment options through media and community programs. For instance, campaigns by the American Society for Reproductive Medicine (ASRM) and collaborations such as the ASRM Clinical Embryology Learning Laboratory (CELL) — established in October 2024 with the Society for Reproductive Biologists and Technologists (SRBT) — are enhancing the standards of embryology education and practice.

2. Integration of Genetic Testing and Preimplantation Genetic Testing (PGT)

A major technological advancement reshaping the ART industry is the adoption of Preimplantation Genetic Testing (PGT). PGT leverages Next-Generation Sequencing (NGS) to identify chromosomal abnormalities before embryo transfer, enabling physicians to select the healthiest embryos.

This technology has proven particularly beneficial for older women or those with recurrent IVF failures, significantly improving implantation rates and live birth outcomes. The increasing use of PGT-A (aneuploidy testing) reflects the broader shift toward personalized reproductive medicine, empowering patients to make data-driven reproductive choices.

3. Artificial Intelligence and IVF Automation Revolution

Artificial Intelligence (AI) and automation are transforming the landscape of reproductive medicine. AI-assisted imaging and data analytics enable clinics to track embryo development and predict implantation success with unprecedented precision.

Time-lapse imaging systems such as EmbryoScope and AI-driven tools from innovators like Alife Health and TMRW Life Sciences are optimizing lab operations and enhancing embryo selection accuracy.

In July 2024, Hamilton Thorne Ltd., a Canadian firm, launched EmbryoView Pro, an AI-powered embryo monitoring system that evaluates embryo health in real-time. This technology improves IVF outcomes and supports the growing trend of smart fertility labs, where automation minimizes human error and increases success rates.

4. Surge in Fertility Preservation and Egg Freezing

A defining trend in the U.S. ART market is the growing adoption of egg freezing among women who wish to delay motherhood for personal or professional reasons. Advancements in vitrification (rapid-freezing technology) have dramatically improved egg survival rates, leading to higher IVF success.

Large corporations like Apple, Meta (Facebook), and Google now include egg freezing benefits in their employee health packages — a move that aligns workplace inclusivity with reproductive autonomy.

Moreover, fertility clinics across the U.S. are promoting fertility preservation campaigns that empower women to “take control of their biological clock.” The social normalization of elective egg freezing signals a cultural and medical shift toward proactive fertility management.

Challenges in the U.S. ART Market

1. High Treatment Costs

One of the most significant barriers in the American ART industry is cost. A single IVF cycle can range from US$ 12,000 to US$ 20,000, excluding medications and additional procedures like PGT, embryo freezing, or storage. Given that multiple cycles are often required, the total expense can become prohibitive.

Limited insurance coverage exacerbates the issue, restricting ART access for middle- and lower-income families. This financial disparity highlights the inequality in reproductive healthcare, despite technological and procedural advances.

2. Regulatory and Ethical Complexities

The U.S. ART market operates within a fragmented regulatory framework. Unlike pharmaceuticals or medical devices, ART clinics face limited federal oversight, leading to inconsistencies in quality and reporting standards.

While organizations like the FDA, CDC, and ASRM provide guidelines, most regulation occurs at the state level, resulting in varying rules on surrogacy, embryo storage, and donor anonymity. These variations can confuse patients and complicate compliance for providers, especially as cross-border fertility tourism rises.

Moreover, ethical debates over embryo selection, genetic modification, and commercialization of reproduction continue to influence public policy and perception.

Market Segmentation Overview

By Technology:

In Vitro Fertilization (IVF)

Artificial Insemination (AI-IUI)

Frozen Embryo Transfer (FET)

Others

By End Use:

Hospitals

Fertility Clinics

Other End Users/Providers

This segmentation highlights how fertility clinics dominate ART adoption due to their specialized infrastructure, skilled embryologists, and integrated genetic testing capabilities.

Key Players in the U.S. Assisted Reproductive Technology Market

Prominent companies driving innovation in the U.S. ART market include:

Cosmos Biomedical Ltd.

Microm U.K. Ltd.

CooperSurgical, Inc.

FUJIFILM Irvine Scientific, Inc.

Cryolab Ltd.

Vitrolife AB

Merck KGaA

Ferring B.V.

These players are focusing on strategic collaborations, R&D investments, and AI-enabled fertility platforms to improve outcomes, expand service offerings, and enhance patient experience.

For instance, CooperSurgical and FUJIFILM Irvine Scientific continue to lead with advanced embryo culture media and cryopreservation solutions, while Merck KGaA invests heavily in personalized fertility treatment ecosystems powered by digital tools.

Future Outlook: The Digital Fertility Revolution

The next decade of the U.S. ART market will be defined by digital transformation, precision medicine, and greater inclusivity. Innovations such as wearable fertility trackers, remote consultations, and AI-based embryo selection will make ART more accessible and efficient.

Government efforts to broaden insurance coverage for fertility care — alongside public advocacy for reproductive rights — will further drive growth. Meanwhile, the integration of genomic testing, machine learning, and robotic lab automation will mark the dawn of next-generation fertility clinics.

As the boundaries between biotechnology, data science, and reproductive medicine blur, the U.S. is poised to lead the global ART revolution.

Final Thoughts

The United States Assisted Reproductive Technology Market reflects the intersection of science, society, and compassion. With a forecasted market value of US$ 9.31 billion by 2033, ART in the U.S. is evolving beyond infertility treatment — it’s becoming a movement toward empowered parenthood, technological excellence, and inclusive healthcare.

While cost and regulation remain challenges, innovations in AI, genetics, and cryopreservation continue to bridge the gap between biological limitations and human aspirations. For many, ART is not merely a medical intervention but a pathway to hope, reshaping the future of family and fertility in America.

Source: Renub Research — United States Assisted Reproductive Technology Market Report 2025–2033